Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

389
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
389
Urinary Tract Infection I: Introduction01:26

Urinary Tract Infection I: Introduction

932
Urinary tract infections (UTIs) impact various parts of the urinary system, including the kidneys, ureters, bladder, and urethra. These infections are generally bacterial, with Escherichia coli being the most common causative agent, often originating from the gastrointestinal tract. However, other bacteria, such as Staphylococcus saprophyticus, Klebsiella pneumoniae, and Proteus mirabilis, are also known to cause UTIs. The type, location, and underlying complexity of the UTI guide both...
932
Urinary Tract Infection II: Pathophysiology01:25

Urinary Tract Infection II: Pathophysiology

1.0K
The pathophysiology of urinary tract infections (UTIs) encompasses several progressive stages, beginning with bacterial colonization and culminating in potential systemic complications if untreated. UTIs are primarily initiated by bacteria, such as Escherichia coli, which often originate from the gastrointestinal tract and migrate to the urinary system through the periurethral area. This migration can occur via several routes, including improper hygiene practices, sexual activity, or...
1.0K
Urine Studies II: Urine Culture and Sensitivity Test01:26

Urine Studies II: Urine Culture and Sensitivity Test

1.9K
A urine culture and sensitivity test is a diagnostic procedure used to identify urinary tract bacterial infections and determine the most effective antibiotics for treatment. This test is generally preferred when a patient shows manifestations of a urinary tract infection, such as frequent or painful urination, cloudy or foul-smelling urine, or lower abdominal pain.Purpose of the TestThe primary goals of a urine culture and sensitivity test are to:Determine the specific bacteria causing the...
1.9K
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

1.8K
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment for T1DM patients by a neuro-fuzzy inverse optimal controller including multi-step prediction.

ISA transactions·2021
Same author

The updated Charlson comorbidity index is a useful predictor of mortality in patients with Staphylococcus aureus bacteraemia.

Epidemiology and infection·2018
Same author

[Simulation of an outbreak of Acinetobacter baumannii in hospitals].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2017
Same author

The clinical microbiologist before the taxonomic changes in the genus Clostridium.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2016
Same author

Kinetics of Antimicrobial Activity of Amoxicillin/Clavulanic Acid and Metronidazole against β-Lactamase-Producing Bacteroides fragilis Group.

Journal of chemotherapy (Florence, Italy)·2016
Same author

[Changes in the epidemiology of Clostridium difficile infection during 2005-2014 in Salamanca, Spain].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2016

Related Experiment Video

Updated: Mar 17, 2026

An In Vitro Bladder Model of Catheter-Associated Urinary Tract Infection
07:57

An In Vitro Bladder Model of Catheter-Associated Urinary Tract Infection

Published on: June 24, 2025

1.4K

In Vitro Activity of Tigemonam Against Urinary Tract Pathogens.

J A Garcia-Rodriguez1, J E Garcia-Sanchez1

  • 1a Department of Microbiology , Clinical Hospital, Faculty of Medicine , Salamanca , Spain .

Journal of Chemotherapy (Florence, Italy)
|July 15, 2016
PubMed
Summary
This summary is machine-generated.

Tigemonam shows good in vitro activity against Enterobacteriaceae, including common urinary pathogens like E. coli and P. mirabilis. However, it is inactive against Pseudomonas aeruginosa, with activity comparable to cefotaxime but less than norfloxacin and aztreonam.

More Related Videos

Models of Murine Vaginal Colonization by Anaerobically Grown Bacteria
08:53

Models of Murine Vaginal Colonization by Anaerobically Grown Bacteria

Published on: May 25, 2022

4.7K
Recurrent Escherichia coli Urinary Tract Infection Triggered by Gardnerella vaginalis Bladder Exposure in Mice
08:53

Recurrent Escherichia coli Urinary Tract Infection Triggered by Gardnerella vaginalis Bladder Exposure in Mice

Published on: December 4, 2020

7.0K

Related Experiment Videos

Last Updated: Mar 17, 2026

An In Vitro Bladder Model of Catheter-Associated Urinary Tract Infection
07:57

An In Vitro Bladder Model of Catheter-Associated Urinary Tract Infection

Published on: June 24, 2025

1.4K
Models of Murine Vaginal Colonization by Anaerobically Grown Bacteria
08:53

Models of Murine Vaginal Colonization by Anaerobically Grown Bacteria

Published on: May 25, 2022

4.7K
Recurrent Escherichia coli Urinary Tract Infection Triggered by Gardnerella vaginalis Bladder Exposure in Mice
08:53

Recurrent Escherichia coli Urinary Tract Infection Triggered by Gardnerella vaginalis Bladder Exposure in Mice

Published on: December 4, 2020

7.0K

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Antibiotic resistance is a growing global health concern.
  • Novel antimicrobial agents are crucial for combating resistant bacterial infections.
  • Understanding the in vitro activity spectrum of new antibiotics is essential for guiding clinical use.

Purpose of the Study:

  • To evaluate the in vitro antibacterial activity of tigemonam.
  • To compare tigemonam's efficacy against Enterobacteriaceae and Pseudomonas aeruginosa with established antibiotics.
  • To determine the Minimum Inhibitory Concentrations (MICs) of tigemonam against various bacterial strains.

Main Methods:

  • Agar dilution method was employed for susceptibility testing.
  • Thirty-two strains of Pseudomonas and 960 strains of Enterobacteriaceae were tested.
  • Tigemonam was compared against aztreonam, cefotaxime, gentamicin, and norfloxacin.

Main Results:

  • Tigemonam demonstrated good activity against Enterobacteriaceae, with low MICs for E. coli and P. mirabilis.
  • MIC50 for P. mirabilis was 0.01 mg/L and MIC90 for P. mirabilis and P. vulgaris was 0.03 mg/L.
  • Tigemonam was inactive against Pseudomonas aeruginosa (MICs > 128 mg/L), similar to cefotaxime and gentamicin, but less effective than norfloxacin and aztreonam.

Conclusions:

  • Tigemonam is a promising agent against Enterobacteriaceae, including common urinary pathogens.
  • Its lack of activity against Pseudomonas aeruginosa limits its potential clinical applications for certain infections.
  • Further investigation into tigemonam's spectrum and resistance mechanisms is warranted.